Spots Global Cancer Trial Database for Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Official Title: Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Study ID: NCT05223582
Study Description
Brief Summary: The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk locoregional prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
